ABSTRACT
The clinical development of ara-C as the most effective agent for treatment of acute my eloid leukemias interested chemists in synthesizing new nucleoside analogs. The plethora of analogs generated from the chemical pharmacopoeia provides an opportunity to under stand the structure-based differences in the metabolic and mechanistic aspects. At the same time, we are faced with a challenge of identifying the selective target and/or diseases for each of these newer nucleoside analogs.
